by Ken Wahl, VP Business Development, Data Insights, Guidepoint Nevro Corp. (NYSE: NVRO) is a key player in the spinal cord stimulation (SCS) market. Since FDA approval of the Senza system in 2015, Nevro has taken ~15% market share from well-established market leaders Abbott/St. Jude, Medtronic and Boston Scientific. The U.S. SCS market was an […]

by Kenny Dolgin, Data Insights, Guidepoint Abiomed, Inc. (NYSE: ABMD) is a leader in the percutaneous heart pump device market, having launched its first Impella device in 2008 and have since released four iterations with varying flow rates. From May 2013 to May 2018, Abiomed’s stock price delivered a 5-year CAGR of 75%, making it […]

by Kenny Dolgin, Data Insights, Guidepoint Edwards Lifesciences Corp. (NYSE: EW) is a leader in the approximately $3 billion transcatheter heart valve (THV) market, having launched their first SAPIEN valve in the U.S. in 2011 and now having released their third generation valve. From 2013 to 2017, Edwards’ stock price delivered a 5-year CAGR of […]

by Kenny Dolgin, Data Insights, Guidepoint Penumbra Inc. (NYSE: PEN) is a key player in the treatment for ischemic stroke, having received FDA approval for the first aspiration-based thrombectomy system in 2007 and having since launched five new generations of the device. In the U.S., Penumbra caters to a total addressable market of approximately $1.5 […]

Guidepoint works with over 3,250 clients, including 9 of the top 10 global consulting firms.   Our network is made up of over 900,000 Advisors covering all sectors, regions and relevant industries. These Advisors are C-Suite Decision Makers, Customers, Suppliers, Operations, Procurement, etc.   Our dedicated global servicing teams provide strategic recruiting resources and can […]

by Ken Wahl, Data Insights, Guidepoint Shire Plc’s (NYSE: SHPG) US hemophilia sales have faced much competition in recent years. In particular, their leading hemophilia A treatment Advate, an older, shorter-acting recombinant factor VIII, is facing many new US market entrants with longer half-lives. However, the global hemophilia portfolio including Adynovate has managed to maintain […]

As an expert network, we’ve received a lot of requests that start with ”this is going to sound strange” or “you probably don’t know anyone”. Very rarely was that client right. With over 800,000 advisors and deep expertise in custom recruiting new experts, we have the tools and the people to get you answers to [...]

When hours can make the difference between capitalizing on an opportunity or coming up empty handed, the ability to find accurate, timely insights is a critical advantage for businesses. Here’s how we help our clients get the right information to make decisions with confidence within that crucial time period. Through the unmatched speed of our offerings, […]

With the rise of misinformation in all areas of mass media, the need for airtight credibility is now more crucial than ever before. Without it, it would be impossible to make the right decisions with the right insights. Client need: Identifying your business need and matching it to the right expert with the most relevant [...]

There was a time when lack of information was a pressing business challenge. But, in the current climate of over-communication and alternative facts, the challenge for today’s decision makers isn’t finding information, but how to identify the right information.   In an era of self-selection and content curation, it’s easy to let overconfidence, lack of […]